- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Patent holdings for IPC class A61P 19/10
Total number of patents in this class: 1905
10-year publication summary
|
61
|
63
|
38
|
91
|
139
|
120
|
105
|
109
|
105
|
33
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2961 |
41 |
| Daiichi Sankyo Company, Limited | 1829 |
28 |
| Novartis AG | 11238 |
24 |
| Osaka University | 3143 |
16 |
| Radius Health, Inc. | 94 |
16 |
| The Regents of the University of California | 18943 |
15 |
| Chugai Seiyaku Kabushiki Kaisha | 1259 |
13 |
| Bristol-myers Squibb Company | 5080 |
12 |
| Merck Patent GmbH | 5909 |
12 |
| Sanofi | 3836 |
12 |
| Boehringer Ingelheim International GmbH | 4629 |
11 |
| Amgen Inc. | 3779 |
11 |
| Asahi Kasei Pharma Corporation | 144 |
11 |
| Kyowa Hakko Kirin Co., Ltd. | 285 |
11 |
| Bayer Schering Pharma AG | 460 |
10 |
| Wisconsin Alumni Research Foundation | 3774 |
10 |
| Astellas Pharma Inc. | 1145 |
10 |
| Mochida Pharmaceutical Co., Ltd. | 334 |
10 |
| Shionogi & Co., Ltd. | 914 |
10 |
| sanofi-aventis | 427 |
10 |
| Other owners | 1612 |